Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Trimble

Physician Assistant Chestnut Hill, MA Physician Assistant

NPI 1912593971 CMS profile 9708284

300 Boylston St Ste 300, Chestnut Hill, MA 02467

Open in the dashboard

General payments

$1,852

67 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Trimble of Chestnut Hill, MA is reported in the CMS Open Payments database as having received $1,852 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $705 24
2024 General $864 35
2023 General $147 2
2022 General $66 3
2021 General $69 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Trimble
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jennifer Trimble were reported at $705. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jennifer Trimble Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $69 $132 $37–$438 $132
2022 $66 $155 $48–$522 $149
2023 $147 $167 $52–$557 $160
2024 $864 $178 $55–$600 $164
2025 $705 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $395 8 payments
  2. Endo USA, Inc. $364 12 payments
  3. Astellas Pharma US Inc $144 7 payments
  4. Ferring Pharmaceuticals Inc. $144 7 payments
  5. Pfizer Inc. $133 4 payments
  6. Janssen Biotech, Inc. $110 5 payments
  7. Urogen Pharma, Inc. $91 3 payments
  8. PROCEPT BioRobotics Corporation $79 2 payments
  9. EMD Serono, Inc. $63 3 payments
  10. Teleflex LLC $58 3 payments
  11. Other $271 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,852 67 payments
Products named General payments · program years 2021–2025
  1. INTERSTIM $395 8 payments
  2. XIAFLEX $387 13 payments
  3. XTANDI $259 10 payments
  4. AVEED $157 7 payments
  5. ORGOVYX $133 4 payments
  6. TALZENNA $133 4 payments
  7. ERLEADA $110 5 payments
  8. ADSTILADRIN $71 4 payments
  9. JELMYTO $59 2 payments
  10. AQUABEAM SYSTEM $57 1 payment
  11. Other $422 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

471

Median for Physician Assistant: 241

Drug cost

$33,180

Median for Physician Assistant: $4,110

Branded share of claims

36.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 23 $17,333
Myrbetriq Mirabegron Brand 18 $8,782
Estradiol Generic 37 $2,569
Tamsulosin Hcl Generic 128 $1,235
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 62 $1,052
Methenamine Hippurate Generic 12 $627
Cefuroxime Cefuroxime Axetil Brand 35 $558
Cefdinir Generic 14 $213
Ciprofloxacin Hcl Generic 27 $182
Finasteride Generic 13 $138

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$41,175

Of which drugs: $13,338

Medicare patients

306

Average age 77

Services billed

1,705

124 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Cancer 34%
Ischemic heart disease 30%
Diabetes 27%
Depression 27%
Chronic kidney disease 26%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 15 76 $10,735

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $42
  • PFIZER INC. $33
$74 — —
ERLEADA
  • Janssen Biotech, Inc. $71
$71 — —
XIAFLEX
  • Endo USA, Inc. $55
  • Endo Pharmaceuticals Inc. $11
$66 — —
JELMYTO
  • UROGEN PHARMA, INC. $59
$59 — —
LUPRON DEPOT
  • AbbVie, Inc. $46
$46 — 76

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record